Research Paper Volume 16, Issue 6 pp 5452—5470

Figure 1. CPL alleviate high-sucrose intake-induced fat accumulation, hyperglycemia, dyslipidemia and disorders of hepatic and renal function. (A) Experimental design. (B) Weight of the mice. (C) Liver index. (D) Fat index. (E) Fasting blood glucose (FBG). (F) Homeostasis model assessment of insulin resistance (HOMA-IR). (G) The oral glucose tolerance test (OGTT) and area under the curve (AUC) were calculated for blood glucose levels during the OGTT. (H) Serum lipid levels. (I) Hepatic and renal function. n = 10 mice per group. The data are presented as the mean ± SEM. Statistical analysis was performed using Student’s t test. ^*p < 0.05, ^**p < 0.01, Abbreviation: ns: not significant.